“Meet face-to-face with international pharmaceutical companies, stay informed about the latest industry trends and remain one step ahead of a constantly changing pharmaceutical market.”

Mix with the world of Pharma products, people & solution, CPhI Worldwide brings an unparalleled week of networking and business opportunities.

The show attracts a quality audience from all industry sectors looking for innovation and eager to find new pharmaceutical ingredients, contract services, technology and packaging for their businesses.

With the aim to promote business across the globe, GRACURE PHARMACEUTICALS LTD participated at CPHI worldwide, 2015 which was held at Madrid, Spain from 13^th October’2015 to 15^th October’2015.

CPHI worldwide gave us a platform to showcase and exchange our services. The companies hailed from various sectors like contract manufacturing, API manufacturers, distributors and marketers.

CPHI Worldwide is a platform that allows one to get in touch with the top pharmaceutical companies of various domains like contract manufacturing, API manufacturers, marketers, distributors, etc. There is no involvement of third party. Henceforth, a direct interaction of the buyers and sellers that led to a clear flow of innovative ideas between the both. Also the buyer gets the innovative product under one roof.

The USP of the firm like EU-GMP, TGA-Australia, Ukraine GMP, WHO GMP approved facility at Bhiwadi, Rajasthan; quality meeting International standards; providing quality products at affordable prices were the key points that were highly appreciated by all and helped in generating quality business.

Overall an outstanding outcome of our visit to CPHI worldwide 2015 which will soon yield us fruitful results in terms of quality business!!

Asia is likely to soon overtake North America in terms of overall pharma sales. This is a trend that is likely to continue for the foreseeable future due to broad macroeconomic drivers such as population and income growth. It is true that Japan and China will continue to dominate pharma sales in Asia. For example, with annual pharma sales of over $80 billion, China is already more than five times the size of the Indian domestic pharma market in terms of value. However, rapid annual market revenue growth rates of over 10–12 per cent in countries such as India are likely to see an expanding interest by global pharma companies in other Asian markets including India.

Another factor affecting the global pharma industry is the increasing pace of branded products losing patent exclusivity in developed markets. Much of this phenomenon has impacted mass market small molecule products. Generic companies around the world including Indian companies have and will continue to reap the benefits of this trend. Another opportunity that is opening up for Indian pharma majors is the beginning of the trend of more complex biologic products losing patent exclusivity in developed markets through competition from biosimilars. This phenomenon is likely to significantly expand the opportunities for many Indian pharma companies with strong international operations. Today, pharma exports from India are nearly as large as the domestic pharma market. As this international business for India pharma majors grows, companies are gearing up to further strengthen their internal capabilities to manage these international businesses through a mix of strong local affiliate presence and strong centralised capabilities, often located and/or managed from India.

Even within India, the growing size of the domestic market, the growing scale of Indian pharma companies and the expanding introduction of new products into the market is leading to a significant increase in competitive intensity. Growing scrutiny of promotional tactics by the government is only increasing the pressure for local companies to find out ways to differentiate themselves in the market. Increasingly, companies are focusing on enhancing their internal strategies and capabilities in this hyper-competitive environment.

Emerging needs of the Indian pharma industry

The evolving global and domestic market dynamics are likely to result in significant opportunities and challenges for pharma companies operating in India, both Indian companies as well as Indian affiliates of MNC companies. Some key issue areas are already starting to capture the attention of leadership teams within the industry.

Growth acceleration with sales and marketing excellence

With an increasingly competitive domestic market in India, pharma companies are being faced with the challenge of having to work much harder to drive revenue growth. Companies will need to increasingly develop ways to systematically identify unmet customer opportunities and barriers, identify and prioritise specific promotional strategies to take advantage of the opportunities and execute tactics successfully. Having robust sales and marketing capabilities is going to be critical for pharma companies to differentiate themselves in the market. Developing these capabilities will require people with advanced skills, robust and well-defined processes, and enabling tools and techniques.

Given the evolving market dynamics the traditional sales structure, processes and sales reps skills are not enough to succeed today. Companies are starting to explore ways to assess their current sales capabilities, identify and prioritise gap areas, and invest in ways to systematically upgrade themselves in the prioritised areas through a combination of talent management and enabling tools and processes. Strong investments in CRM and reporting technologies to enable the sales force and sales management are good examples of that.

More and more pharma companies in India are starting to think about the best return from their investments by strengthening their marketing capabilities. Decision-driven analytics to support marketing investment decisions is an area that many companies are taking a serious look at. Evolving customer needs require sharper segmentation, targeting and positioning.

Commercial organisation design

The role of different players within the healthcare space is continuing to evolve in India. Some changes include the expansion of corporate hospitals and pharmacy chains, the increasing importance of medical insurance companies and the growing role of patients in decision making, especially with ready access to information and prevalence of the social media. All these changes along with increasing competition, trend toward consolidation and likelihood of more government scrutiny around pharma promotional tactics will require companies to continuously re-evaluate how to most appropriately structure their commercial organisations. More and more companies are also realising that there is a strong need to strengthen roles such as key account management and medical within their sales organisations.

Opportunity assessment

With the continuous growth of the Indian healthcare market, both multinational pharma companies as well as India pharma companies have had the need to evaluate the potential opportunity to introduce new products and services. Companies cannot afford the downstream implications of poor forecasts including sub-optimal investments, guidance to corporate strategy and sales force attrition. The need for robust methodologies is also increasing as companies invest in more specialty areas such as oncology and immunology.

As Indian pharma companies start work to take advantage of the growth opportunities and appropriately address the challenges to come, there will be a growing demand for best in class ideas around marketing and sales issues.

IPHEX’2015, an exhibition that gave us, Gracure Pharmaceuticals Ltd., a global arena to showcase the wide range of products covering various therapeutic segments, to the global audience.

Portraying our four segments of business models: Sales & Marketing, Contract manufacturing, Out licensing of Dossiers & Contract manufacturing and Contract Development & Contract manufacturing, each and every query was handled superbly by the superior management, in order to result them into business growth.

Having a global presence in over 20+ countries, we at Gracure Pharmaceuticals catered to the various business queries of the clients/visitors across the globe who attended the exhibition.

The USP of the firm like EU-GMP, TGA-Australia approved facility at Bhiwadi, Rajasthan, the high levels of quality meeting the international standards were the starting points to generate the curiosity in the buyers’ minds to have detailed information about the company and its various therapeutic categories.

It was a great platform to know about various firms and what they are dealing into. A great platform where the drugs, pharmaceuticals and healthcare industry came together all under one roof.

The tact to deal with various buyers across the globe, the information about the company & its wide product range, the high quality standards and the best part the team work and coordination among each other was the best thing to learn.

Everybody did the best to support each other.

Glad to attend IPHEX for the first time. Waiting to attend the next IPHEX’2016 to have a new lesson again!!